Stereotactic body radiation therapy provides local control in pediatric cancer patients

Stereotactic body radiation therapy (SBRT) appears to provide durable local control with minimal severe toxicities in pediatric and adolescent/young adult (AYA) patients with cancer, according to a study.

Researchers identified 9 published studies with primary outcomes of 1-year and 2-year local control and incidence of acute and late grade 3 to 5 toxicities, with secondary outcomes of 1-year overall survival and progression-free survival.

Included were 142 pediatric and AYA patients with 217 lesions treated with SBRT.

The estimated local control rates for 1- and 2-years were 83.5% and 74.0%, respectively.

The estimated rate of acute and late grade 3 to 5 toxicities was 75.4% and 27.1%, respectively. The estimated 1-year OS and PFS rates were 75.4% and 27.1%, respectively.

In sarcoma-predominant cohorts, dose escalation may potentially improve local control without an increase in toxicity.

Dose escalation may result in improved LC for sarcoma-predominant cohorts without a subsequent increase in toxicity.

Reference
Singh R, Valluri A, Didwania P, et al. Efficacy and Safety of Stereotactic Body Radiation Therapy for Pediatric Malignancies: The LITE-SABR Systematic Review and Meta-Analysis. Adv Radiat Oncol. 2023;8(2):101123. doi: 10.1016/j.adro.2022.101123. PMID: 36845622; PMCID: PMC9943773.